Abstract
The IGF system plays a major role in growth, development and maintenance of homeostasis in normal cells and also contributes towards proliferation of malignant cells. Any disruption in the IGF system has its implications on growth retardation, atherosclerosis, insulin resistance and cancer. Imbalances in the IGF axis are known to contribute towards the progression of breast cancer. Due to the ubiquitous nature of the components of the IGF system, targeting specific members of the axis has gained attention over the past decades. The most elaborately investigated component as a therapeutic target in the system is the IGF-IR and studies have been pursued to inhibit IGF-IR by the administration of monoclonal antibodies and tyrosine kinase inhibitors. Very recently, a novel cell death receptor that binds specifically to IGFBP-3 was identified. It has also been shown that the IGFBP-3/IGFBP-3 receptor may be impaired in breast and prostate cancer. In this review, we present the mechanisms used to target the IGF system in various diseased states, emphasizing on breast cancer. We further discuss currently available therapeutic approaches and summarize the latest patents published in the field of IGF-I/IGF-IR and IGFBP-3/IGFBP-3R systems.
Keywords: Anti-cancer drugs, breast cancer, IGF system, IGF-IR, IGFBP-3, IGFBP-3R, tyrosine kinase inhibitors, patents, ENDOCRINE DISORDERS, cancer therapy, homeostasis
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Volume: 6 Issue: 2
Author(s): Lathika Mohanraj and Youngman Oh
Affiliation:
Keywords: Anti-cancer drugs, breast cancer, IGF system, IGF-IR, IGFBP-3, IGFBP-3R, tyrosine kinase inhibitors, patents, ENDOCRINE DISORDERS, cancer therapy, homeostasis
Abstract: The IGF system plays a major role in growth, development and maintenance of homeostasis in normal cells and also contributes towards proliferation of malignant cells. Any disruption in the IGF system has its implications on growth retardation, atherosclerosis, insulin resistance and cancer. Imbalances in the IGF axis are known to contribute towards the progression of breast cancer. Due to the ubiquitous nature of the components of the IGF system, targeting specific members of the axis has gained attention over the past decades. The most elaborately investigated component as a therapeutic target in the system is the IGF-IR and studies have been pursued to inhibit IGF-IR by the administration of monoclonal antibodies and tyrosine kinase inhibitors. Very recently, a novel cell death receptor that binds specifically to IGFBP-3 was identified. It has also been shown that the IGFBP-3/IGFBP-3 receptor may be impaired in breast and prostate cancer. In this review, we present the mechanisms used to target the IGF system in various diseased states, emphasizing on breast cancer. We further discuss currently available therapeutic approaches and summarize the latest patents published in the field of IGF-I/IGF-IR and IGFBP-3/IGFBP-3R systems.
Export Options
About this article
Cite this article as:
Mohanraj Lathika and Oh Youngman, Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489211795328512
DOI https://dx.doi.org/10.2174/157489211795328512 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Estrogen Activates Classical and Alternative Mechanisms to Orchestrate Neuroprotection
Current Neurovascular Research Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Menopause, A Universal Female Experience: Lessons from Mexico and Central America
Current Women`s Health Reviews Clinical Aspects of Clara Cell 10-kDa Protein / Uteroglobin (Secretoglobin 1A1)
Current Pharmaceutical Design Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Structure, Biological Properties and Applications of Marine-derived Polysaccharides
Current Organic Chemistry Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Synthesis of Novel 1,4-Substituted 1,2,3-Triazoles by Water-Soluble (Salicyladimine) <sub>2</sub>Cu Complex Catalyzed Azide-Alkyne Cycloaddition in Water
Letters in Organic Chemistry FLT3 as a Therapeutic Target in Childhood Acute Leukemia
Current Drug Targets Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry On the Comparison of Classifiers for Microarray Data
Current Bioinformatics Meet Our Editorial Board Member
Current Proteomics High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters Human Growth Hormone Induced Cholestatic Hepatitis in a Growth Hormone Deficient Patient with Short Stature
Current Drug Safety Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry High Catalytic Activity of Pd Nanoparticles Synthesized from Green Alga Chlorella vulgaris in Buchwald-hartwig Synthesis of N-Aryl Piperazines
Current Organocatalysis